5-propynyluracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-propynyluracil: a PYaraU metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	131813
CHEMBL ID	4642216
SCHEMBL ID	13296
MeSH ID	M0221579

Synonyms (19)

Synonym
unii-90ni1zdq6n
134700-29-1
90ni1zdq6n ,
2,4(1h,3h)-pyrimidinedione, 5-(1-propynyl)-
5-pu
5-prop-1-ynyl-1h-pyrimidine-2,4-dione
5-propynyluracil
SCHEMBL13296
UJBCLAXPPIDQEE-UHFFFAOYSA-N
5-(1-propynyl)uracil
DTXSID10158869
2,4(1h,3h)-pyrimidinedione,5-(1-propyn-1-yl)-
FT-0713422
Q27271337
BS-47624
5-(prop-1-yn-1-yl)pyrimidine-2,4(1h,3h)-dione
CHEMBL4642216
CS-0436837
F77583

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
"Netivudine dosing produces complete inhibition of plasma dihydropyrimidine dehydrogenase."	( Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Callaghan, J; Crome, P; Fraser, I; Frick, L; Peck, R; Posner, J; Wiggs, R; Wootton, R, 1996)	0.55

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID1664571	Antitubercular activity against Mycobacterium tuberculosis H37Ra assessed as bacterial growth inhibition by MABA relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664575	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664574	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664579	Antitubercular activity against Mycobacterium bovis BCG assessed as bacterial growth inhibition by MABA relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664576	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (66.67)	18.2507
2000's	1 (16.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.29 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.37 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (16.67%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.01	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytosine [no description available]	2	1	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	4.47	5	1	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.25	1	0	carbohydrazide	antitubercular agent; drug allergen
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	2.25	1	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
2-aminopurine 2-Aminopurine: A purine that is an isomer of ADENINE (6-aminopurine).. aminopurine : Any purine having at least one amino substituent.. 2-aminopurine : The parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position.	2.01	1	0	2-aminopurines; nucleobase analogue	antimetabolite
2,6-diaminopurine 9H-purine-2,6-diamine : A member of the class of 2,6-diaminopurines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by amino groups.	2.01	1	0	2,6-diaminopurines; primary amino compound	antineoplastic agent
5-propynylarabinofuranosyluracil 5-propynylarabinofuranosyluracil: potent inhibitor of VZV	4.06	3	1
n(4)-methylcytosine N(4)-methylcytosine : A pyrimidone that is cytosine bearing an N(4)-methyl substituent.	2	1	0	aminopyrimidine; methylcytosine; pyrimidone	metabolite
arabinofuranosyluracil Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.	4.06	3	1
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.25	1	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

chemdatabank.com